Anti-EGFR single-chain Fvs and anti-EGFR antibodies

US5844093A · kind A · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• A. Cathrine Kettleborough · Watford, GB
• Mary M. Bendig · Vésenaz, CH
• Keith H. Ansell · Hatfield, GB
• Detlef Gussow · Darmstadt, DE
• Jaume Adan · Mataró, ES
• Francesc Mitjans · Igualada, ES
• Elisabet Rosell · Barcelona, ES
• Francesc Blasco · Sant Just Desvern, ES
• Jaume Piulats · Barcelona, ES

Key dates

• Filing date: Nov 17, 1995
• Grant date: Dec 1, 1998
• Expiry date: Nov 17, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to new anti-EGFR antibodies and single-chain Fvs (scFvs) thereof which can be obtained from phage-antibody libraries constructed from cells of an immunized mammalian, preferably a mouse. Two of the single-chain Fvs isolated from the phage-antibody libraries were engineered to create partially humanized whole antibody molecules. These chimeric anti-EGFR antibodies contain constant regions of human immunoglobulins, and can be used as well as the single-chain Fvs as agents for the diagnosis and therapy of human tumors.